AU2002356469A1 - Methods of compositions for normalizing lipid levels in mammalian tissues - Google Patents
Methods of compositions for normalizing lipid levels in mammalian tissues Download PDFInfo
- Publication number
- AU2002356469A1 AU2002356469A1 AU2002356469A AU2002356469A AU2002356469A1 AU 2002356469 A1 AU2002356469 A1 AU 2002356469A1 AU 2002356469 A AU2002356469 A AU 2002356469A AU 2002356469 A AU2002356469 A AU 2002356469A AU 2002356469 A1 AU2002356469 A1 AU 2002356469A1
- Authority
- AU
- Australia
- Prior art keywords
- cgrp
- receptor
- agonist
- amylin
- high affinity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Child & Adolescent Psychology (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009201147A AU2009201147A1 (en) | 2001-11-26 | 2009-03-26 | Methods and Compositions for Normalizing Lipid Levels in Mammalian Tissues |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33342201P | 2001-11-26 | 2001-11-26 | |
US60/333,422 | 2001-11-26 | ||
NZ515731 | 2001-11-26 | ||
NZ51573101 | 2001-11-26 | ||
PCT/NZ2002/000262 WO2003045424A1 (fr) | 2001-11-26 | 2002-11-26 | Procedes et compositions pour normaliser les niveaux lipidiques dans les tissus mammaliens |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2002356469A2 AU2002356469A2 (en) | 2003-06-10 |
AU2002356469A1 true AU2002356469A1 (en) | 2003-06-10 |
Family
ID=26652295
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002356469A Withdrawn AU2002356469A1 (en) | 2001-11-26 | 2002-11-26 | Methods of compositions for normalizing lipid levels in mammalian tissues |
AU2009201147A Abandoned AU2009201147A1 (en) | 2001-11-26 | 2009-03-26 | Methods and Compositions for Normalizing Lipid Levels in Mammalian Tissues |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2009201147A Abandoned AU2009201147A1 (en) | 2001-11-26 | 2009-03-26 | Methods and Compositions for Normalizing Lipid Levels in Mammalian Tissues |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1461068A4 (fr) |
JP (1) | JP2005523418A (fr) |
CN (1) | CN1617737A (fr) |
AU (2) | AU2002356469A1 (fr) |
CA (1) | CA2471833A1 (fr) |
WO (1) | WO2003045424A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000018392A1 (fr) | 1998-09-25 | 2000-04-06 | Glycox Corporation Limited | Fructosamine-oxydase: antagonistes et inhibiteurs |
AU2003225442B2 (en) | 2002-03-08 | 2010-02-04 | Philera New Zealand Limited | Preventing and/or treating cardiovascular disease and/or associated heart failure |
EP1539129A4 (fr) | 2002-08-20 | 2006-03-08 | Protemix Corp Ltd | Formes posologiques et traitements s'y rapportant |
PT1778618E (pt) | 2004-07-19 | 2014-03-04 | Philera New Zealand Ltd | Síntese de trietilenotetraminas |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
RS61793B1 (sr) | 2011-05-20 | 2021-06-30 | H Lundbeck As | Anti-cgrp kompozicije i njihova upotreba |
DK2709663T3 (da) | 2011-05-20 | 2019-05-20 | Alderbio Holdings Llc | Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere |
NZ717704A (en) | 2011-05-20 | 2022-08-26 | H Lundbeck As | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
TWI753471B (zh) * | 2013-07-03 | 2022-01-21 | 美商艾爾德生物製藥股份有限公司 | 使用抗cgrp抗體之葡萄糖代謝的調節 |
WO2020146527A1 (fr) | 2019-01-08 | 2020-07-16 | Alder Biopharmaceuticals, Inc. | Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8720115D0 (en) | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
US5175145A (en) * | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
WO1994021665A1 (fr) * | 1993-03-24 | 1994-09-29 | Amylin Pharmaceuticals, Inc. | Recepteurs clones et methodes de criblage associees |
JPH10504457A (ja) | 1994-08-16 | 1998-05-06 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | カルシトニンレセプター |
AU6596096A (en) * | 1996-07-23 | 1998-02-10 | Smithkline Beecham Corporation | Calcitonin gene-related peptide receptor component factor (houdc44) |
CN1055640C (zh) * | 1996-11-29 | 2000-08-23 | 沃维汉 | 人降钙素基因相关肽脂质体组合物及其制法 |
WO1999040928A1 (fr) * | 1998-02-13 | 1999-08-19 | Amylin Pharmaceuticals, Inc. | Nouveaux composes a activite mixte par rapport a l'amyline |
-
2002
- 2002-11-26 CN CNA028275691A patent/CN1617737A/zh active Pending
- 2002-11-26 CA CA002471833A patent/CA2471833A1/fr not_active Abandoned
- 2002-11-26 WO PCT/NZ2002/000262 patent/WO2003045424A1/fr active Application Filing
- 2002-11-26 AU AU2002356469A patent/AU2002356469A1/en not_active Withdrawn
- 2002-11-26 JP JP2003546925A patent/JP2005523418A/ja active Pending
- 2002-11-26 EP EP02803945A patent/EP1461068A4/fr not_active Withdrawn
-
2009
- 2009-03-26 AU AU2009201147A patent/AU2009201147A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2009201147A1 (en) | 2009-04-23 |
CN1617737A (zh) | 2005-05-18 |
AU2002356469A2 (en) | 2003-06-10 |
JP2005523418A (ja) | 2005-08-04 |
WO2003045424A1 (fr) | 2003-06-05 |
EP1461068A1 (fr) | 2004-09-29 |
CA2471833A1 (fr) | 2003-06-05 |
EP1461068A4 (fr) | 2006-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009201147A1 (en) | Methods and Compositions for Normalizing Lipid Levels in Mammalian Tissues | |
US7803557B2 (en) | Methods for identification of eicosapentaenoic acid analogs using anti-inflammatory receptors | |
Wang et al. | Inflammation, a link between obesity and cardiovascular disease | |
Kraus et al. | Ghrelin levels are increased in alcoholism | |
Canatan et al. | Relationship among levels of leptin and zinc, copper, and zinc/copper ratio in plasma of patients with essential hypertension and healthy normotensive subjects | |
Nakahara et al. | Comparison of feeding suppression by the anorexigenic hormones neuromedin U and neuromedin S in rats | |
WO2006060743A2 (fr) | Genes et polypeptides associes au transport du glucose et procedes d'utilisation de ceux-ci | |
Tollet-Egnell et al. | Growth hormone-mediated alteration of fuel metabolism in the aged rat as determined from transcript profiles | |
Nellemann et al. | Kinetics and utilization of lipid sources during acute exercise and acipimox | |
US20040038861A1 (en) | Methods and compositions for normalizing lipid levels in mammalian tissues | |
AU2016361783A1 (en) | Agonist of spexin-based galanin type 2 receptor and use thereof | |
WO2004055201A2 (fr) | Cholesterol 24-hydroxylase (cyp46) utilisee en tant que cible therapeutique pour le traitement de la maladie d'alzheimer | |
WO2000075166A1 (fr) | Recepteur de l'hormone concentratrice de la melanine | |
Wasilewski et al. | Role of G protein-coupled orphan receptors in intestinal inflammation: novel targets in inflammatory bowel diseases | |
WO2009036768A2 (fr) | Diagnostic de la prise de poids potentielle chez un sujet | |
Sochal et al. | Diagnostic value of chemerin in lower gastrointestinal diseases—A review | |
NZ542281A (en) | Methods and compositions for normalizing muscle lipid levels using CGRP-1 | |
Wan et al. | association between peripheral adiponectin and lipids levels and the therapeutic response to donepezil treatment in Han Chinese patients with Alzheimer’s disease | |
Oana et al. | DNA microarray analysis of white adipose tissue from obese (fa/fa) Zucker rats treated with a β3-adrenoceptor agonist, KTO-7924 | |
CA2577176A1 (fr) | Procede de detection d'agoniste ou d'antagoniste transporteur de carnitine et utilisations | |
US7947458B1 (en) | Placental human neurokinin B precursor | |
Vargas-Sánchez et al. | PPARα and PPARβ/δ Expression is Associated with Proinflammatory Markers in an Obese Pediatric Population | |
WO2000034791A1 (fr) | Essais de composes augmentant l'activite de la phospholipase a2 | |
Harant et al. | Atrial natriuretic peptide contribution to lipid | |
Nugent | OB-AGE, an EU project to tackle the metabolic syndrome: project update. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JUL 2004 |
|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ METHODS AND COMPOSITIONS FOR NORMALIZING LIPID LEVELS IN MAMMALIAN TISSUES |
|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |